Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Multiple Myeloma
Multiple Myeloma Treatment Regimens
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
FDA Approves New Treatment Option for Multiple Myeloma
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
Mass Spectrometry for Detection of Monoclonal Gammopathy of Undetermined Significance
Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Antibiotic Prophylaxis Shown to Reduce Infection Risk for Patients With Newly Diagnosed Multiple Myeloma
Prophylactic antibiotics trended toward reducing infection risk at 3 months if given in first 2 to 3 months after MM diagnosis; however, it had no effect on mortality rates.
Modified Bortezomib, Lenalidomide, Dexamethasone Induction Regimen Efficacious, Tolerable for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
A modified induction protocol (VRd lite) demonstrated high efficacy with better tolerability in patients with NDMM who are eligible for ASCT.
Next post in Multiple Myeloma
